Phosphorylethanolamine

Alzheimer's Disease Biomarkers and Clinical Trials Insight 2028 Report Highlights: Global Alzheimer's Disease Antibodies Market Opportunity: > USD 5 Billion Alzheimer's Disease Clinical Trials Insight: > 200 Drugs In Trials Alzheimer's Disease Biomarkers Sourced During Clinical Trials Alzheimer's Disease Insight By Classification Insight On Biomarkers Sourced From Trials By Drugs & Indication Biomarker Name & Function Insight By Drug Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication Download Report Sample: http://biomarkersinsights.com/alzheimers-disease-biomarkers-and-clinical-trials-insight-2028 Alzheimer disease is a neurodegenerative disorder which is characterized by significant cognitive deficits, behavioral changes, sleep disorders, and loss of functional autonomy. The number of patients suffering from Alzheimer disease is growing rapidly as the population ages worldwide. Alzheimer disease represents the major cause of dementia and has become a major public health issue. The diagnosis at a late stage is relatively easy. However, a delay in the diagnosis is damageable for the handling of patients in terms of optimal medical and social care. Moreover, early diagnosis is essential to start treatments, which are conceivably more effective at the early stage. Therefore, the interest of scientists is mainly focused on early diagnosis of disease and to propose personalized therapeutic solutions to individual patients. For this, scientists have identified several biomarkers. A biomarker (biological marker) is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers have played valuable roles in the diagnostic algorithm of many diseases, as well as the assessment of disease progression and potential recurrence. Apart from this, biomarkers also play critical role in the design and conduction of research protocols targeting Alzheimer disease. They may improve the selection of participants and render more biologically homogeneous the sampled populations. Several clinical trials are ongoing which are evaluating novel biomarkers for the Alzheimer disease. For instance, in a recent clinical trial, the blood samples were drawn from patients enrolled in an FDA-approved Phase II trial at Dartmouth Hitchcock Medical Center in New Hampshire and then shipped to the Brain Chemistry Labs for analysis. The study revealed that the ratio of two molecules, 2-aminoethyl dihydrogen phosphate and taurine, allows to relaiably discriminate samples of early-stage Alzheimer’s patients from controls. This research does not depend upon on amyloid and the assay can be performed on analytical equipment that is already present in most large hospitals. As per our report findings, the global Alzheimer drug market is expected to surpass US$ 5 Billion by 2028. Factors such as the increasing prevalence of Alzheimer disease and growing focus on neurological biomarker research are expected to propel the growth of the market during the forecast period. Additionally, increasing awareness about neurological diseases, coupled with developing healthcare infrastructure, are creating growth opportunities for the market players. However, the concerns associated with biomarker like measurement errors, cost and others hamper the market growth. The global Alzheimer disease biomarker market is highly competitive in nature. Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios, which help them, meet the growing consumer demand. Collaboration is one of the major strategies adopted by the Alzheimer disease biomarker market players to enlarge customer base worldwide, which also permits them to maintain their brand name globally. For instance, Probiodrug has entered into agreement with Crossbeta Biosciences; to use the latter’s proprietary technology in support of Probiodrug’s biomarker development activities for Alzheimer’s disease. The other players in market include Teva Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline, and others. Our report provides in-depth analysis on the currently available biomarker across various stages of clinical trial. The study also provides insights into commercially available drugs for Alzheimer disease, and major drugs in research and development. This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges that will determine the market’s future growth.